02:56 , Nov 21, 2014 |  BC Extra  |  Clinical News

St. Jude, UCL gene therapy cuts bleeding in hemo B trial

Patients receiving scAAV2/8-LP1-hFIXco, a gene therapy developed by St. Jude Children's Research Hospital and University College London (UCL) , maintained higher Factor IX levels and had markedly fewer spontaneous bleeding episodes in a Phase I...
08:00 , Feb 10, 2014 |  BioCentury  |  Finance

uniQure completes comeback

uniQure completes comeback Dutch gene therapy play uniQure N.V. (NASDAQ:QURE) is back on the public markets after a two-year hiatus. The company has taken advantage of renewed interest in gene therapy as well as the...
07:00 , Sep 2, 2013 |  BC Week In Review  |  Clinical News

AAV2-GDNF: Phase I started

uniQure said researchers at the University of California , San Francisco and the NIH's National Institute of Neurological Disorders and Stroke (NINDS) began an open-label, dose-escalation Phase I trial to evaluate AAV2-GDNF in about 24...
08:00 , Feb 11, 2013 |  BC Week In Review  |  Company News

uniQure B.V., Xenon deal

Xenon said it received an undisclosed milestone payment from uniQure under a 2001 deal granting Amsterdam Molecular Therapeutics Holding N.V. , which dissolved into uniQure last year, access to its IP related to lipoprotein lipase...
08:00 , Nov 5, 2012 |  BC Week In Review  |  Clinical News

Glybera alipogene tiparvovec regulatory update

The European Commission approved Glybera alipogene tiparvovec from uniQure to treat lipoprotein lipase (LPL) deficiency in patients with recurring, acute pancreatitis. Glybera is the first gene therapy approved by regulatory authorities outside of China. uniQure...
01:08 , Nov 3, 2012 |  BC Extra  |  Top Story

EC approves gene therapy Glybera

The European Commission approved Glybera alipogene tiparvovec from uniQure B.V. (Amsterdam, the Netherlands) to treat lipoprotein lipase (LPL) deficiency in patients with recurring, acute pancreatitis. Glybera is the first gene therapy approved outside of China....
07:00 , Jul 30, 2012 |  BioCentury  |  Regulation

Persistence pays off

After two and a half years and four tries, uniQure B.V. 's gene therapy Glybera alipogene tiparvovec finally won the backing of the European Medicines Agency's CHMP. Approval by the European Commission would make Glybera...
07:00 , Jul 23, 2012 |  BC Week In Review  |  Clinical News

Glybera alipogene tiparvovec regulatory update

EMA's CHMP recommended approval of an MAA from uniQure for Glybera alipogene tiparvovec to treat lipoprotein lipase (LPL) deficiency in patients with severe or multiple pancreatitis attacks, despite dietary fat restrictions. CHMP said it reversed...
23:33 , Jul 20, 2012 |  BC Extra  |  Company News

CHMP backs Glybera for LPL deficiency

EMA's CHMP recommended approval of an MAA from uniQure B.V. (Amsterdam, the Netherlands) for Glybera alipogene tiparvovec to treat lipoprotein lipase (LPL) deficiency in patients with severe or multiple pancreatitis attacks, despite dietary fat restrictions....
07:00 , Jul 2, 2012 |  BC Week In Review  |  Clinical News

AAV2-GDNF: Phase I start

Next month, researchers at the University of California (San Francisco, Calif.) and the NIH's National Institute of Neurological Disorders and Stroke (NINDS) will begin an open-label Phase I trial to evaluate AAV2-GDNF in about 24...